
    
      This is an international, multicentre, event-driven, randomized, double-blind, parallel
      group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given
      once daily in addition to standard of care, to prevent the progression of chronic kidney
      disease (CKD) or cardiovascular (CV)/renal death.
    
  